These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10029706)

  • 21. Role of Tc-99m tetrofosmin imaging in the examination of patients with breast lesions.
    Schillaci O; Danieli R; Scopinaro F
    Radiology; 1999 Jan; 210(1):284-6. PubMed ID: 9885623
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effect of 153Sm-EDTMP on hematopoiesis and vital organs of 93 patients with bone tumor].
    Deng H; Tan T; Mo T; Zhong S; Kuan A; Hu Y
    Hua Xi Yi Ke Da Xue Xue Bao; 1995 Jun; 26(2):155-9. PubMed ID: 7490021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Samarium-153-EDTMP in bone metastases.
    Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
    J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of axillary lymph node metastasis of breast carcinoma with technetium-99m sestamibi scintimammography.
    Tolmos J; Khalkhali I; Vargas H; Stuntz M; Cutrone J; Mishkin F; Diggles L; Venegas R; Klein S
    Am Surg; 1997 Oct; 63(10):850-3. PubMed ID: 9322655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of technetium-99m sestamibi to indicate breast cancer invasiveness.
    Bourgeois P
    Eur J Nucl Med; 1995 Jun; 22(6):581-5. PubMed ID: 7556307
    [No Abstract]   [Full Text] [Related]  

  • 26. Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources.
    Dillehay GL; Ellerbroek NA; Balon H; Brill DR; Grigsby PW; Macklis RM; Mauch PM; Mian TA; Potters L; Silberstein EB; Williams TR; Wong JC; Gaspar LE;
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1299-307. PubMed ID: 16472933
    [No Abstract]   [Full Text] [Related]  

  • 27. New research developments increase therapeutic options for thyroid cancer and bone pain palliation.
    Williams JE
    J Nucl Med; 1997 Nov; 38(11):19N-20N, 26N. PubMed ID: 9374327
    [No Abstract]   [Full Text] [Related]  

  • 28. Invited commentary: one step forward.
    Lastoria S; Piccolo S; Muto P
    J Nucl Med; 2002 Jul; 43(7):916-7. PubMed ID: 12097462
    [No Abstract]   [Full Text] [Related]  

  • 29. [Complementary scintigraphic examinations (99mTc-MDP, 99mTc-MIBI and Octreoscan) in breast neoplasm assessment].
    Stefănescu C; Chossiere L; Rusu V; Meignan M
    Rev Med Chir Soc Med Nat Iasi; 1996; 100(3-4):165-8. PubMed ID: 9455458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The value of Sm-153-EDTMP for treatment of metastatic bone pain and improving quality of life].
    Jiang CY; Zhu BL; Zhang YJ
    Zhonghua Zhong Liu Za Zhi; 1994 Mar; 16(2):118-21. PubMed ID: 7523052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scintimammography: the new role of technetium-99m Sestamibi imaging for the diagnosis of breast carcinoma.
    Khalkhali I; Iraniha S; Diggles LE; Cutrone JA; Mishkin FS
    Q J Nucl Med; 1997 Sep; 41(3):231-8. PubMed ID: 9274131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scintimammography in breast cancer diagnosis.
    Newman J
    Radiol Technol; 1998; 70(2):153-68; quiz 169-72. PubMed ID: 9839329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pronounced therapeutic effect of samarium 153-ethylenediaminetetramethylene phosphonate in an orthotopic human osteosarcoma tibial tumor model.
    Winderen M; Kjønniksen I; Fodstad O
    J Natl Cancer Inst; 1995 Feb; 87(3):221-2. PubMed ID: 7707409
    [No Abstract]   [Full Text] [Related]  

  • 34. 177Lu-EDTMP: a potential therapeutic bone agent.
    Ando A; Ando I; Tonami N; Kinuya S; Kazuma K; Kataiwa A; Nakagawa M; Fujita N
    Nucl Med Commun; 1998 Jun; 19(6):587-91. PubMed ID: 10234664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tc-99m sestamibi scintimammography: where is it now?
    Schillaci O; Scopinaro F
    Cancer Biother Radiopharm; 1999 Dec; 14(6):417-22. PubMed ID: 10850328
    [No Abstract]   [Full Text] [Related]  

  • 36. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial.
    Collins C; Eary JF; Donaldson G; Vernon C; Bush NE; Petersdorf S; Livingston RB; Gordon EE; Chapman CR; Appelbaum FR
    J Nucl Med; 1993 Nov; 34(11):1839-44. PubMed ID: 8229221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of patient positioning in scintimammography.
    Mirzaei S
    Eur J Nucl Med; 2001 Jul; 28(7):941-2. PubMed ID: 11504096
    [No Abstract]   [Full Text] [Related]  

  • 38. High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma.
    Franzius C; Bielack S; Sciuk J; Vollet B; Jürgens H; Schober O
    Nuklearmedizin; 1999; 38(8):337-40. PubMed ID: 10615669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
    Zafeirakis A; Zissimopoulos A; Baziotis N; Limouris GS
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):91-102. PubMed ID: 21068716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advancing medical care: the role of nuclear medicine in radioguided surgery, part II: sentinel node dissections.
    Kotz D
    J Nucl Med; 1998 Dec; 39(12):13N, 15N, 21N. PubMed ID: 9867131
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.